We are a biopharmaceutical company focused on reducing the manufacturing costs of (biosimilars of) Monoclonal Antibody (mAbs) biological drugs, in order to increase patient access to this important family of therapeutics. We have developed technology capable of reducing the COGS more than 10-fold, which allows healthy profitability even at 50% of the pricing of originator drugs. We are scaling up our platform to commercialize it to third parties and we are also developing our own pipeline of biosimilar products. We aim to become a global reference in the manufacturing of monoclonal antibody biologicals, biosimilars and biobetters.
|
|
|
1-10 employees
View all BiosanaPharma employees
|
|
Biotechnology
|
|
Bargelaan 200, Leiden, South Holland 2333CW, NL
|
|
2012
|
|
Biotechnology, Monoclonal Antibodies, Biosimilar Mabs, Low Cost Of Goods
|
Ard Tijsterman is the CEO of BiosanaPharma. To contact Ard Tijsterman email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.